12 Month Price Forecast For COCP
Distance to COCP Price Forecasts
COCP Price Momentum
🤔 Considering Cocrystal Pharma (COCP)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 4:50 AM UTC
COCP Analyst Ratings & Price Targets
Based on our analysis of 2 Wall Street analysts, COCP has a consensus that is bullish. The median price target is $8.00, with forecasts ranging from $7.00 to $10.00. Currently, there are 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With COCP currently trading at $2.00, the median price forecast suggests a 300.0% upside. The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 400.0% upside, while Raghuram Selvaraju at HC Wainwright & Co. provides the most conservative target, suggesting a 250.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COCP Analyst Consensus
COCP Price Target Range
Latest COCP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COCP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 22, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| May 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Apr 4, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Jan 3, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $10.00 |
| Dec 4, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Oct 4, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Jun 2, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| May 24, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $12.00 |
| Jan 24, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $35.00 |
| Nov 7, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $42.00 |
| Nov 12, 2020 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $4.50 |
| Jul 8, 2020 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Jun 16, 2020 | Noble Capital Markets | Outperform | Initiates | $0.00 |
Stocks Similar to Cocrystal Pharma Inc
The following stocks are similar to Cocrystal Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cocrystal Pharma Inc (COCP) Financial Data
Cocrystal Pharma Inc has a market capitalization of $19.99M with a P/E ratio of -1.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -68.9%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Cocrystal Pharma Inc (COCP) Company Overview
About Cocrystal Pharma Inc
Develops antiviral therapeutic treatments for viral diseases.
The company utilizes structure-based technologies to discover and develop antiviral drugs, primarily targeting serious viral infections like hepatitis C, influenza, and coronaviruses. It generates revenue through collaboration agreements, such as those with Merck and Kansas State University, which facilitate the development of proprietary antiviral agents.
Cocrystal Pharma is actively advancing multiple drug candidates through various clinical trial phases, including CC-31244 for hepatitis C and CC-42344 for influenza. The company is strategically positioned in the biotechnology sector, focusing on high-need therapeutic areas, and is headquartered in Bothell, Washington.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
12
CEO
Dr. Sam Lee Ph.D.
Country
United States
IPO Year
2012
Website
www.cocrystalpharma.comCocrystal Pharma Inc (COCP) Latest News & Analysis
U.S. stocks declined, with the Dow Jones index dropping over 100 points towards the end of Tuesday's trading session.
A decline in the Dow Jones index signals market weakness, potentially impacting investor sentiment and leading to increased volatility or shifts in investment strategies.
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
23 days agoCocrystal Pharma plans to extend enrollment in its Phase 2a study of the influenza drug CDI-42344 due to low infection rates among participants challenged with H3N2.
Low enrollment in Cocrystal's flu study may delay results and impact timelines, affecting investor confidence and stock performance in the biotech sector.
Cocrystal Pharma, Inc. (Nasdaq: COCP) will participate in the Virtual Investor Summit Microcap Forum in August and the H.C. Wainwright 26th Annual Global Investment Conference in September.
Cocrystal Pharma's participation in key investor conferences signals potential growth and visibility, which may attract interest and influence stock performance.
CoCrystal Pharma (NASDAQ:COCP) will present at the virtual Investor Summit Microcap Forum on August 20, 2024, with management available for one-on-one meetings.
CoCrystal Pharma's presentation at the Investor Summit highlights potential growth opportunities in antiviral therapeutics, attracting investor interest and possibly impacting stock performance.
Cocrystal Pharma, Inc. (COCP) shows potential as a stock pick after hitting a key support level and experiencing a "golden cross" with its 50-day moving average surpassing the 200-day average.
Cocrystal Pharma's "golden cross" signals potential bullish momentum, suggesting a favorable entry point for traders anticipating upward price movement.
Cocrystal Pharma, Inc. (Nasdaq: COCP) reported Q1 2024 financial results and provided updates on its antiviral pipeline and upcoming business milestones.
Cocrystal Pharma's financial results and updates on its antiviral pipeline indicate potential growth and risk factors, influencing stock performance and investor sentiment.
Frequently Asked Questions About COCP Stock
What is Cocrystal Pharma Inc's (COCP) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Cocrystal Pharma Inc (COCP) has a median price target of $8.00. The highest price target is $10.00 and the lowest is $7.00.
Is COCP stock a good investment in 2025?
According to current analyst ratings, COCP has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for COCP stock?
Wall Street analysts predict COCP stock could reach $8.00 in the next 12 months. This represents a 300.0% increase from the current price of $2.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cocrystal Pharma Inc's business model?
The company utilizes structure-based technologies to discover and develop antiviral drugs, primarily targeting serious viral infections like hepatitis C, influenza, and coronaviruses. It generates revenue through collaboration agreements, such as those with Merck and Kansas State University, which facilitate the development of proprietary antiviral agents.
What is the highest forecasted price for COCP Cocrystal Pharma Inc?
The highest price target for COCP is $10.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 400.0% increase from the current price of $2.00.
What is the lowest forecasted price for COCP Cocrystal Pharma Inc?
The lowest price target for COCP is $7.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 250.0% increase from the current price of $2.00.
What is the overall COCP consensus from analysts for Cocrystal Pharma Inc?
The overall analyst consensus for COCP is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are COCP stock price projections?
Stock price projections, including those for Cocrystal Pharma Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
